Venture Capital

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

Why the $1.4B McConnell Group’s move to The Real Brokerage signals a major shift in how top agents are choosing to build their businesses and their wealth.

A new NOAA rule speeds up permits for mining critical metals from the ocean floor, a move hailed by industry but condemned by scientists as a grave risk.

As new federal rules threaten the hemp beverage industry, Nowadays hires a former alcohol regulator to help build a legitimate, sustainable future.

DLP Capital's Don Wenner lands a top spot on a prestigious impact list, proving that building affordable housing can also build a financial powerhouse.

Amid explosive growth, GMVA hires a new CFO to manage its expansion and lead the financial strategy for its upcoming Agentic AI healthcare platform.

In just months, Upscale AI raised over $300M to tackle the critical networking bottleneck slowing down AI, betting on open standards to win the market.

LiveWorld unveils a new AI roadmap for pharma, promising a safer, human-guided approach to tackle compliance and build trust in a high-risk industry.

With a fresh $10M, Furl is unleashing agentic AI to autonomously fix the vulnerabilities that overburdened security and IT teams can only find.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

Brands are ditching costly ads for immersive, creator-led events. See how Gallery Club House is rewriting the rules for Big Game marketing in 2026.

With AWS's Mark Relph joining its AI Council, Qlik reinforces its strategy to move enterprise AI from experimentation to governed, real-world application.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.

A new reseller partnership between OculusIT and Evisions combines managed IT services with enterprise reporting to help universities combat financial strain.

A new journal issue reveals how venture capital, advanced clinical insights, and patient-centered drug design are creating a new era in heart failure care.

The Drug Information Association's new platform aims to help startups overcome funding and regulatory hurdles, connecting them to investors and experts.

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

After a $16.5M funding round, the smart-shipping innovator hires a top finance exec to scale its attack on the $35B problem of spoiled medicine.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.